Elisa Petris

Elisa is a Managing Partner of Syncona Investment Management Limited.

She is one of the firm’s founding team members and brings over a decade of experience building and shaping Syncona’s portfolio of life science companies. Elisa serves on the Boards of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics, and previously held Board positions at Blue Earth Diagnostics (acquired by Bracco Imaging in 2019), Neogene Therapeutics (acquired by AstraZeneca in 2023), and Achilles Therapeutics. She played a pivotal role in the founding of Quell, Blue Earth, Achilles, and Beacon, leading their operational and strategic setup. At Beacon, she also served as Chief Business Officer and as a member of the Executive Leadership Team during the company’s first 18 months.

Before joining Syncona, Elisa was a Senior Associate at Michel Dyens & Co., advising on healthcare transactions, and a member of the Life Sciences team at L.E.K. Consulting in London, where she worked with biotech, pharma, and private equity clients.

Elisa is also Co‑founder of Invest in Equity, an international initiative dedicated to promoting and supporting the advancement of women in life science investing careers. The organisation brings together investors, LPs and industry leaders across biotech, medtech and healthtech to build a more inclusive and gender‑equitable investment ecosystem.

She holds a PhD in Molecular Biology from Imperial College London and an MBA from the London Business School.

Syncona portfolio companies

• Quell Therapeutics (Board member)
• Beacon Therapeutics (Board member)
• Forcefield Therapeutics (Board member)